Last updated: February 27, 2026
What is the Drug and Its Indications?
NDC 83324-0012 corresponds to Lomitapide, marketed under the brand name Juxtapid. It is approved by the FDA for managing homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder characterized by extremely high LDL cholesterol levels resistant to standard therapies.
Market Size and Potential
The HoFH patient population remains limited, with estimates ranging from 1,300 to 3,000 diagnosed individuals in the United States and similar numbers globally. The market hinges on:
- Prevalence: 1 in 1 million for homozygous FH.
- Diagnosis rates: Approximate 50% diagnosed in some regions.
- Treatment adoption: Limited to severe cases refractory to LDL-lowering therapies.
Key Market Dynamics
| Factor |
Detail |
| Patient Population |
1,300-3,000 globally, predominantly in North America and Europe |
| Market Penetration |
Moderate; driven by diagnosis rates and physician awareness |
| Competition |
PCSK9 inhibitors (alirocumab, evolocumab), lomitapide (marketed as Juxtapid) |
| Reimbursement |
Variable; high cost influences access and prescribing patterns |
Pricing Overview
Juxtapid (lomitapide) is priced at approximately $310,000 annually per patient in the U.S., assuming a typical regimen of 30 mg daily. The high cost derives from its orphan drug status, limited patient population, and complex manufacturing.
Price Comparison
| Drug |
Approved Indication |
List Price (USD/year) |
Market Status |
| Juxtapid (83324-0012) |
Homozygous FH |
~$310,000 |
On market since 2012 |
| Mipomersen |
Familial hypercholesterolemia |
~$175,000 |
Discontinued |
| PCSK9 inhibitors |
Homozygous and heterozygous FH |
$14,000 - $16,000 |
Widely prescribed |
Cost Factors
- Orphan drug designation limits price competition.
- Manufacturing complexity increases production costs.
- Limited patient pool supports high per-unit pricing.
Market Trends and Demand Forecasts
The overall market for lomitapide is constrained by the small patient population. A conservative forecast suggests:
- Growth rate: 2-3% annually, driven by increased diagnosis.
- Market expansion: Slow, unless new indications emerge or biosimilar competition develops.
- Reimbursement trends: Stricter cost-effectiveness assessments could pressure prices downward.
Price Projection Scenarios
| Scenario |
Assumptions |
Projected Price (USD/year) |
Timeline |
| Base Case |
Continued rarity, stable competition, no biosimilars |
$310,000 |
2023-2028 |
| Optimistic |
New approvals or expanded indications; improved diagnosis |
$290,000 |
2023-2028 |
| Pessimistic |
Biosimilar entry reduces market dominance |
$200,000 |
2025-2028 |
Competitive and Regulatory Outlook
- Patent protections for Juxtapid are expected to extend to 2024-2025.
- No biosimilar or generic versions are currently approved, ensuring market exclusivity.
- Significant labeling restrictions limit use to severe cases, constraining market expansion.
Key Challenges
- Small patient base limits revenue potential.
- Pricing pressures from payers and health authorities.
- Competition from emerging lipid-lowering therapies, including gene editing and antisense technologies.
Key Takeaways
- NDC 83324-0012 (lomitapide/Juxtapid) holds a niche position with high prices driven by orphan drug status.
- Market size remains minimal, constrained by diagnosis rates and severity criteria.
- Short- to mid-term price stability expected barring biosimilar development or expanded indications.
- Reimbursement landscape remains complex, with significant influence from health technology assessments.
- Investment risk remains high due to dependency on small patient populations and regulatory exclusivities.
Frequently Asked Questions
Q1: How does the price of lomitapide compare with other lipid-lowering therapies?
A1: It is significantly higher, around $310,000 per year, versus PCSK9 inhibitors at $14,000-$16,000 annually.
Q2: What factors could drive down the price of NDC 83324-0012?
A2: Biosimilar or generic entry, expanded indications, or increased competition could lower prices.
Q3: How many patients are estimated to be eligible for this therapy?
A3: Approximately 1,300 to 3,000 patients globally, primarily in high-income regions.
Q4: Are there upcoming regulatory changes that could affect pricing?
A4: No significant changes expected in the near term; patent expiration around 2024-2025 may open generic opportunities.
Q5: What therapeutic alternatives could threaten lomitapide’s market share?
A5: PCSK9 inhibitors and emerging gene therapies could provide alternatives, especially if priced more competitively.
References
- U.S. Food and Drug Administration. (2012). Juxtapid (lomitapide) prescribing information.
- Orphanet. (2021). Homozygous familial hypercholesterolemia.
- EvaluatePharma. (2022). Lipid-lowering drugs market forecast.
- IQVIA. (2022). Biopharma market insights.
- FDA. (2020). Patent and exclusivity data for lomitapide.
